{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:38:25Z","timestamp":1782949105036,"version":"3.54.5"},"reference-count":147,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer-associated venous thromboembolism (CA-VTE) is a significant complication in oncology, contributing to morbidity, mortality, and increased healthcare utilization. Due to multiple patient- and disease-related factors, patients with cancer are at a markedly elevated risk for VTE, particularly within the first 6 months of diagnosis. The aim of this review is to provide an overview of current challenges and unmet needs in CA-VTE prediction, prevention and management. While the Khorana score remains the most widely used risk stratification tool, its limited sensitivity has prompted the development of more refined models such as PROTECHT, CONKO, ONKOTEV, Vienna-CATS, and COMPASS-CAT. These models incorporate additional clinical variables including cancer subtype, systemic therapies, comorbidities, and emerging biomarkers. However important gaps remain, particularly in addressing bleeding risk, underrepresented racial\/ethnic groups, and adapting to novel cancer therapeutics. Recent clinical trials (AVERT, CASSINI) have supported the use of direct oral anticoagulants (DOACs) for primary and secondary prophylaxis in select high-risk populations. However, anticoagulation strategies in complex populations, including those with thrombocytopenia, brain tumors, or concurrent antiplatelet therapy, remain areas of active investigation. Future directions include the integration of genomics, proteomics, and machine learning into risk modeling to enable precision medicine approaches. Ongoing clinical trials are testing the promise of safer prophylactic and therapeutic strategies. Personalized risk assessment and treatment of CA-VTE remain essential to improving patient outcomes in oncology. By consolidating existing evidence and identifying key unmet needs, this review seeks to guide more personalized and effective management of CA-VTE.<\/jats:p>","DOI":"10.3390\/ijms27041756","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:48:34Z","timestamp":1770889714000},"page":"1756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism"],"prefix":"10.3390","volume":"27","author":[{"given":"Sanober","family":"Nusrat","sequence":"first","affiliation":[{"name":"Hematology-Oncology Section, Department of Internal Medicine, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0565-2118","authenticated-orcid":false,"given":"Sayeed","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY 12208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisha","family":"Beg","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Section, Department of Pediatrics, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Raskob","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: A population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study","volume":"162","author":"Heit","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archinte.167.14.1471","article-title":"Venous thromboembolism in the outpatient setting","volume":"167","author":"Spencer","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2012.10.007","article-title":"Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry","volume":"131","author":"Gussoni","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/jth.15818","article-title":"Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population","volume":"20","author":"Raskob","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Raskob, G. (2024). Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy. Bleeding Thromb. Vasc. Biol., 3.","DOI":"10.4081\/btvb.2024.124"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4137\/CMO.S18991","article-title":"Cancer-associated thrombosis: An overview","volume":"8","author":"Elyamany","year":"2014","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/07357900802656681","article-title":"Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors","volume":"27","author":"Wun","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1002\/ajh.24712","article-title":"The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm","volume":"92","author":"Chen","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/bloodadvances.2021006209","article-title":"Racial disparities in cancer-associated thrombosis","volume":"6","author":"Datta","year":"2022","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/asheducation-2013.1.684","article-title":"Cancer-associated thrombosis","volume":"2013","author":"Connolly","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0049-3848(20)30389-3","article-title":"Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: Past, present and future","volume":"191","author":"Moik","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: A systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2018.05.004","article-title":"Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis","volume":"167","author":"Young","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","article-title":"Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: A systematic review and meta-analysis of randomized controlled trials","volume":"183","author":"Thein","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.4049\/jimmunol.1400329","article-title":"Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop","volume":"193","author":"Rosner","year":"2014","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102827","DOI":"10.1016\/j.ctrv.2024.102827","article-title":"Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation","volume":"130","author":"Hua","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/ijc.27979","article-title":"Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis","volume":"132","author":"Qi","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1182\/blood-2024-211304","article-title":"Outcomes in Patients with Cancer-Associated Venous Thromboembolism Receiving Immune Checkpoint Inhibitors: A Matched Cohort Study","volume":"144","author":"Dave","year":"2024","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Alok","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.thromres.2022.01.006","article-title":"Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy","volume":"213","author":"McCrae","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Nichetti, F., Ligorio, F., Zattarin, E., Signorelli, D., Prelaj, A., Proto, C., Galli, G., Marra, A., Apollonio, G., and Porcu, L. (2019). Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers, 12.","DOI":"10.3390\/cancers12010067"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kroger","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.tru.2021.100075","article-title":"Risk assessment models of cancer-associated thrombosis\u2014Potentials and perspectives","volume":"5","author":"Moik","year":"2021","journal-title":"Throbosis Update"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern. Emerg. Med."},{"key":"ref_43","first-page":"2084","article-title":"Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?","volume":"138","author":"Pelzer","year":"2013","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Ortega","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","article-title":"Mechanisms and biomarkers of cancer-associated thrombosis","volume":"225","author":"Kim","year":"2020","journal-title":"Transl. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1160\/TH10-09-0595","article-title":"Pre-analytical and analytical issues in the analysis of blood microparticles","volume":"105","author":"Yuana","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-03-0198","article-title":"Genetic and plasma markers of venous thromboembolism in patients with high grade glioma","volume":"10","author":"Sciacca","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Oto, J., Navarro, S., Larsen, A.C., Solmoirago, M.J., Plana, E., Hervas, D., Fernandez-Pardo, A., Espana, F., Kristensen, S.R., and Thorlacius-Ussing, O. (2020). MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030840"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4143\/crt.2014.266","article-title":"Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism","volume":"48","author":"Lim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.ejca.2015.07.012","article-title":"Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma","volume":"51","author":"Matsuo","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients","volume":"16","author":"Mauracher","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/ijc.29076","article-title":"Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio","volume":"136","author":"Ferroni","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.04.009","article-title":"Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study","volume":"166","author":"Hisada","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00277-010-1111-1","article-title":"Circulating procoagulant microparticles in cancer patients","volume":"90","author":"Thaler","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Almeida, V.H., Rondon, A.M.R., Gomes, T., and Monteiro, R.Q. (2019). Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis. Cells, 8.","DOI":"10.3390\/cells8070716"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Liu, Y., Gao, L., Fan, Y., Ma, R., An, Y., Chen, G., and Xie, Y. (2023). Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1079719"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1160\/TH08-05-0339","article-title":"Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Iannuzzo","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study","volume":"102","author":"Cesarman","year":"2017","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1634\/theoncologist.2019-0510","article-title":"ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis","volume":"25","author":"Godinho","year":"2020","journal-title":"Oncologist"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","article-title":"External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model","volume":"25","author":"Spyropoulos","year":"2020","journal-title":"Oncologist"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2019.07.005","article-title":"The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism","volume":"181","author":"Mulder","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug\u2013associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"201","author":"Dima","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: A retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11239-019-01845-6","article-title":"Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients","volume":"48","author":"Rotunno","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","article-title":"Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas","volume":"16","author":"Thaler","year":"2014","journal-title":"Neuro-oncology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Committee","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102664","DOI":"10.1016\/j.rpth.2024.102664","article-title":"Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies","volume":"9","author":"Vladic","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.26597","article-title":"Risk assessment models for cancer-associated venous thromboembolism","volume":"118","author":"Dutia","year":"2012","journal-title":"Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: A review","volume":"7","author":"Johnstone","year":"2018","journal-title":"Ann. Palliat. Med."},{"key":"ref_90","first-page":"8547","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_95","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1055\/s-0038-1675577","article-title":"Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus","volume":"2","author":"Pachon","year":"2018","journal-title":"TH Open"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2025-4470","article-title":"Systematic review and meta-analysis of randomized controlled trials on outpatient thromboprophylaxis (OTP) in patients with cancers with khorana score (KS) \u2265 2 receiving chemotherapy","volume":"146","author":"Myat","year":"2025","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group","volume":"341","author":"Samama","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jth.12683","article-title":"Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH","volume":"12","author":"Carrier","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_108","first-page":"386","article-title":"Should postoperative thromboembolism prevention be extended to the post-hospitalization phase?","volume":"126","author":"Irani","year":"1996","journal-title":"Schweiz. Med. Wochenschr."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"ENOXACAN Study Group (1997). Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br. J. Surg., 84, 1099\u20131103.","DOI":"10.1002\/bjs.1800840817"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial","volume":"3","author":"Guntupalli","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"Becattini","year":"2022","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lee, A.Y., Bauersachs, R., Janas, M.S., Jarner, M.F., Kamphuisen, P.W., Meyer, G., and Khorana, A.A. (2013). CATCH: A randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-284"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e12736","DOI":"10.1002\/rth2.12736","article-title":"Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study","volume":"6","author":"Pedrajas","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: A systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1076029617696581","article-title":"Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"24","author":"Mathioudakis","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_117","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients with Active Cancer: A Randomized Clinical Trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","article-title":"Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism","volume":"5","author":"Coleman","year":"2023","journal-title":"JACC CardioOncol"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/1708538120971148","article-title":"Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis","volume":"29","author":"Mokadem","year":"2021","journal-title":"Vascular"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0049-3848(20)30402-3","article-title":"Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis","volume":"191","author":"Lyman","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","article-title":"Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia","volume":"70","author":"Schindewolf","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"364s","DOI":"10.1378\/chest.124.6_suppl.364S","article-title":"New pentasaccharides for prophylaxis of deep vein thrombosis: Pharmacology","volume":"124","author":"Bauer","year":"2003","journal-title":"Chest"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2025.15222","article-title":"Superficial Vein Thrombosis: A Review","volume":"334","author":"Piazza","year":"2025","journal-title":"JAMA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_134","unstructured":"National Comprehensive Cancer Network (2025, January 28). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Cancer-Associated Venous Thromboembolic Disease (Version 2.2025). Available online: www.nccn.org."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: A propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients\u201430 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism","volume":"392","author":"Mahe","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats","volume":"26","author":"Escalante","year":"2021","journal-title":"Oncologist"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.43.6.1111","article-title":"Complications of therapy for venous thromboembolic disease in patients with brain tumors","volume":"43","author":"Levin","year":"1993","journal-title":"Neurology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: A matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/bloodadvances.2022009192","article-title":"DOACs in patients with brain cancers: Promising but still a long way to go","volume":"7","author":"Giustozzi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/bmjspcare-2019-002106","article-title":"Central catheter-associated deep vein thrombosis in cancer: Clinical course, prophylaxis, treatment","volume":"11","author":"Marin","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for Prevention of Venous Thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:50:19Z","timestamp":1770889819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":147,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041756"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041756","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}